Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...

Oprah Winfrey has opened up about one thing she got wrong about ‘thin people’ after taking weight loss drugs on her podcast.

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

If you're one of the 13% of American adults who has taken a GLP-1 drug for weight loss, you may know that while fat seemingly ...

Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...

The media mogul's comments about weight loss drugs and "thin people" have stirred intense reactions across social media platforms.

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal.

Oprah Winfrey opens up on her podcast about her weight-loss journey with anti-obesity GLP-1 medications while chatting with doctors and guests. Plus, the media icon shares how her opinion of "thin ...

With the recent surge in popularity of weight loss drugs like Ozempic, altogether called GLP-1s, there has been renewed scientific interest in understanding how our bodies regulate muscle growth.